Abstract 305P
Background
There is no evidence of effective follow-up for the detection of recurrent head and neck cancer (HNC). There are few reports on the frequency of relapse of platinum-resistant HNC in clinical practice. Local recurrence is often seen during the first two years during which follow-up computed tomography (CT)/magnetic resonance imaging is recommended. The occurrence rate of second cancer (SC) has been reported to be 14.5%.
Methods
We conducted a retrospective analysis to evaluate the clinical course in 374 patients with head and neck squamous cell carcinoma who underwent definitive treatment at our institute between January 1998 and November 2018. The observation period was until January 2019.
Results
Recurrence and/or metastasis of HNC (R/M HNC) and SC were seen in 128 and 34 patients, respectively. The sites of R/M HNC were the hypopharynx, oral cavity, and larynx in 30.5%, 21.9%, and 19.5% of the patients, respectively. The sites of SC were the larynx, hypopharynx, and oropharynx in 38.2%, 26.5%, and 20.6% of the patients, respectively. At the diagnosis of relapse of new cancer, 50% of patients with R/M HNC and 44.1% of those with SC were symptomatic. The most common symptom was pain, while other symptoms were swelling, loss of appetite, hoarseness, dysphagia, dyspnea, cough, and bleeding. The modality of detection of recurrence was highest with CT (60.2%), followed by endoscopy (14.1%) and medical examination (14.1%). The median time to recurrence was 6.9 (range, 0 − 141.8) months, with 75% of recurrences occurring within one year. Furthermore, 4.8% of the recurrences occurred after five years. Platinum-resistant relapse accounted for 26.6% of all patients with R/M HNC and 58.6% of the relapses occurred within six months. The median time to recurrence was 35.5 (range, 1.5 − 240.9) months, with 35.3% of the recurrences occurring after five years.
Conclusions
In clinical practice, it is important to note the timing of rescue treatment during the follow-up period, focusing on imaging and medical examinations and confirming the symptoms within one year of treatment for HNC. During the long-term follow-up, observation for suspected development of SC is necessary.
Clinical trial identification
.
Editorial acknowledgement
.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract